Follicular helper T cells (T FH cells) are a subset of CD4 + T cells that are essential for helping cognate B cells form and maintain the germinal center (GC) reaction and for the development of humoral immune responses. These cells are universally defined by expression of the chemokine receptor CXCR5, which directs them to B cell follicles via gradients of the chemokine CXCL13 (ref. 1). T FH cells also express the transcription factor Bcl-6 and have high expression of the costimulatory receptor ICOS. Both Bcl-6 and ICOS are critical for the differentiation and maintenance of T FH cells 1−4 . In addition, T FH cells secrete large amounts of interleukin 21 (IL-21), which aids in the formation of GCs, isotype switching and the formation of plasma cells 5 . In humans and mice, functionally similar T FH cells can be found in secondary lymphoid organs. CXCR5 + T FH cells are also present in peripheral blood and are found in greater abundance in people with autoantibodies, including patients with systemic lupus erythematosus, myasthenia gravis or juvenile dermatomyositis. However, the function of circulating T FH cells has remained unclear [6] [7] [8] [9] .
A r t i c l e s
Follicular helper T cells (T FH cells) are a subset of CD4 + T cells that are essential for helping cognate B cells form and maintain the germinal center (GC) reaction and for the development of humoral immune responses. These cells are universally defined by expression of the chemokine receptor CXCR5, which directs them to B cell follicles via gradients of the chemokine CXCL13 (ref. 1) . T FH cells also express the transcription factor Bcl-6 and have high expression of the costimulatory receptor ICOS. Both Bcl-6 and ICOS are critical for the differentiation and maintenance of T FH cells 1−4 . In addition, T FH cells secrete large amounts of interleukin 21 (IL-21), which aids in the formation of GCs, isotype switching and the formation of plasma cells 5 . In humans and mice, functionally similar T FH cells can be found in secondary lymphoid organs. CXCR5 + T FH cells are also present in peripheral blood and are found in greater abundance in people with autoantibodies, including patients with systemic lupus erythematosus, myasthenia gravis or juvenile dermatomyositis. However, the function of circulating T FH cells has remained unclear [6] [7] [8] [9] .
T FH cells also have high expression of the inhibitory receptor PD-1 (CD279). Signaling through PD-1 attenuates signaling from the T cell antigen receptor (TCR) and inhibits the population expansion, cytokine production and cytolytic function of T cells. In addition, PD-1 promotes the development of induced regulatory T cells (T reg cells) from naive lymphocytes [10] [11] [12] [13] [14] . PD-1 has two ligands: PD-L1 (B7-H1) and PD-L2 (B7-DC). PD-L1 has wider expression than does PD-L2, but both PD-L1 and PD-L2 can be expressed on GC B cells and dendritic cells 15 . Perturbation studies have suggested critical roles for this pathway in regulating humoral immune responses. However, there are conflicting reports about the function of the PD-1 pathway in controlling humoral immunity. When interactions between PD-1 and its ligand(s) are prevented, some studies have found attenuated humoral responses [16] [17] [18] , whereas others have observed heightened humoral responses 19, 20 .
PD-1 also is found on the CD4 + CXCR5 + subset of cells called 'follicular regulatory T cells' (T FR cells), which express the transcription factors Foxp3, Bcl-6 and Blimp-1 and function to inhibit the GC response [21] [22] [23] . These cells originate from natural T reg cells but have expression of ICOS, CXCR5 and PD-1 similar in amount to that of T FH cells. As ICOS, CXCR5 and PD-1 have been widely used to identify and purify 'T FH cells' , it seems likely that the inability to define clear functions for PD-1 in GC responses derives from experimental systems that contain mixtures of stimulatory T FH cells and inhibitory T FR cells. Separate analyses of the function of PD-1 on T FH cells and T FR cells are needed to elucidate how PD-1 controls humoral immunity and to gain insight into the individual roles of T FR cells and T FH cells in the regulation of antibody production.
Here we found that PD-1-PD-L1 interactions inhibited the number of T FR cells, but not of T FH cells, in the lymph nodes. PD-1-deficient mice had more T FR cells in the lymph nodes than did wild-type mice. PD-1-deficient T FR cells in the lymph nodes had an enhanced ability to suppress both the activation of naive T cells and antibody production in vitro. In addition, we found that T FR cells were present in the peripheral blood of mice and that these circulating cells potently regulated humoral immune responses in vivo. Through the use of transfer approaches, we found that T FH cells in the blood promoted antibody production, whereas T FR cells in the blood strongly inhibited antibody production in vivo. We further found that the PD-1 pathway inhibited the function of T FR cells in the blood and that PD-1-deficient T FR cells in the blood had enhanced suppressive ability in vivo. Together our studies identify a previously unknown immunoregulatory role for the PD-1-PD-L1 pathway in limiting the differentiation and function of T FR cells and further demonstrate the dynamic control of humoral immune responses through the migration of T FR cells from the circulation into the lymph nodes to control antibody production in vivo.
RESULTS

PD-1 controls T FR cells
To analyze the role of PD-1 in controlling T FR cells, we first assessed PD-1 expression on CD4 + T cell subsets in the draining lymph nodes of wild-type C57BL/6 mice immunized subcutaneously with myelin oligodendrocyte glycoprotein peptide (amino acids 35-55) emulsified in complete Freund's adjuvant (collectively called 'MOG' here), an immunization that breaks tolerance and also results in the effective generation of T FH cells 24 . We defined T FR cells as CD4 + ICOS + CXCR5 + Foxp3 + CD19 − , a gating strategy that separated T FR cells from CD4 + ICOS + CXCR5 + Foxp3 − CD19 − T FH cells, the cell type previously thought to solely constitute the CD4 + CXCR5 + gate (Fig. 1a) . T FH cells had higher expression of PD-1 protein than did ICOS + CXCR5 − effector-like cells or ICOS − CXCR5 − naive cells (called 'naive cells' here) in the draining lymph nodes on day 7 after immunization ( Fig. 1b) . Notably, T FR cells had even higher expression of PD-1 protein than did any other CD4 + T cell subset examined, including T FH cells (Fig. 1b) .
To determine the functional importance of PD-1 expression on T FR cells, we immunized wild-type and PD-1-deficient (Pdcd1 −/− ) mice and analyzed T FR cells 7 d later. The frequency of T FR cells in the CD4 + Foxp3 + gate was about 4% in wild-type lymph nodes and <1% of all CD4 + T cells. In contrast, the frequency of T FR cells in Pdcd1 −/− mice was about 10% of the CD4 + Foxp3 + gate and >2% of all CD4 + T cells (Fig. 1c,d ). Because the total number of CD4 + T cells was typically about twofold higher in the PD-1-deficient lymph nodes than in wild-type lymph nodes, a twofold-greater frequency of T FR cells indicated an approximately fourfold-greater absolute number of T FR cells (data not shown). When determined as a percentage of all CD4 + ICOS + CXCR5 + cells (and therefore as the percentage of CD4 + T cells that could respond to CXCL13 and migrate to the B cell zone), Pdcd1 −/− T FR cells constituted 50% of that population, whereas wild-type T FR cells constituted only about 20% (Fig. 1d) . We also observed a much greater frequency of T FR cells in Pdcd1 −/− mice when we immunized the mice with other classic B cell antigens, such as the hapten NP (4-hydroxy-3-nitrophenylacetyl) conjugated to ovalbumin (NP-OVA; Supplementary Fig. 1 ). We did not find a significant difference in the frequency of Foxp3 − T FH cells (called 'T FH cells' here) when determined as a percentage of all CD4 + T cells in wild-type and Pdcd1 −/− mice on day 7 after immunization with MOG (Fig. 1e) or NP-OVA (Supplementary Fig. 1 ).
As PD-1 can be expressed by many types of hematopoietic cells, including T cells, B cells, macrophages and some dendritic cells 15 , we next investigated whether PD-1 regulates T FR cells directly by controlling their generation from Foxp3 + T reg cells. To track the fate of Foxp3 + cells after transfer into wild-type mouse recipients, we used antigen-specific Foxp3 + T cells from 2D2 mice, which have transgenic expression of a MOG-specific TCR, for these studies. We sorted Foxp3 + T reg cells from wild-type 2D2 or Pdcd1 −/− 2D2 mice that expressed a Foxp3-green fluorescent protein (GFP) reporter (Foxp3-GFP reporter mice), then transferred 2 × 10 5 wild-type or Pdcd1 −/− 2D2 CD4 + CXCR5 − Foxp3 + cells into wild-type recipient mice. We immunized the recipients with MOG and analyzed cells in the draining lymph nodes 7 d later. A greater frequency (Fig. 1f,g ) and absolute number (Fig. 1h) of Pdcd1 −/− 2D2 T reg cells than wildtype 2D2 T reg cells upregulated CXCR5 and thus differentiated into T FR cells. The greater frequency of Pdcd1 −/− T FR cells in the immunized recipients of cell transfer was similar to but slightly less than the greater frequency of T FR cells in immunized mice lacking PD-1 on all cells (Fig. 1d,g ). These results demonstrated that PD-1 controlled the differentiation of Foxp3 + T reg cells into T FR cells. 
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As CD25 (the α-chain of the receptor for IL-2) is often used as a marker for T reg cells, we next compared CD25 expression on wild-type and Pdcd1 −/− T FR cells immediately after isolation (Fig. 2a) . Pdcd1 −/− T FR cells had lower expression of CD25 than did wild-type T FR cells (Fig. 2b) . The attenuated CD25 expression in PD-1-deficient T FR cells was probably not due to less activation because expression of the early activation marker CD69 was almost completely identical on wildtype and Pdcd1 −/− T FR cells (Fig. 2c) . To compare the proportion of wild-type and Pdcd1 −/− T FR cells that were proliferating on day 7 after immunization with MOG, we examined expression of Ki67, a marker widely used to identify cells that are actively dividing. Wild-type CXCR5 -ICOS + effector cells, T FH cells and T FR cells had high expression of Ki67. In contrast, wild-type CXCR5 -ICOS -'naive' cells, which lacked expression of CD69 and CD25, had no Ki67 staining, consistent with their designation as naive (Fig. 2d) . Wild-type T FR cells had much higher expression of Ki67 than did Pdcd1 −/− T FR cells (Fig. 2d) Fig. 2 ). Additionally, there was low but substantial expression of PD-L1 on wild-type and Pdcd1 −/− T FR cells (Supplementary Fig. 2 ). Together these data indicated that PD-1 was important in regulating the number of T FR cells in vivo.
PD-1-deficient T FR cells can home to GCs
We next compared the ability of wild-type and PD-1-deficient T FR cells to enter the GC to inhibit the GC response. First we evaluated GC formation in lymph node sections collected 7 d after immunization with MOG. We identified GCs by the binding of peanut agglutinin and positive staining for the GC marker GL7 and lack of staining for immunoglobulin D (IgD; Fig. 3a) . We determined that these GCs were active on the basis of their robust expression of Ki67 (Fig. 3b) . Similar to published reports 21, 22 , we found CD4 + Foxp3 + T FR cells in the GCs of immunized mice (Fig. 3c) . The Foxp3 protein in the T FR cells was mostly nuclear, given its localization together with the DNA-intercalating dye DAPI (Fig. 3d) .
We then investigated whether the phenotypically distinct PD-1-deficient T FR cells were able to migrate to GCs similarly to wild-type T FR cells because blockade of PD-1 can prolong the TCR 'stop signal' and diminish T cell migration 25 . We immunized wild-type and PD-1-deficient mice with MOG and analyzed lymph node sections 7 d later for expression of IgD, GL7 and Foxp3 (Fig. 3e) . Although the GC area ( Fig. 3f) and number of GCs per lymph node (data not shown) were equivalent in wild-type and Pdcd1 −/− mice, there were slightly more Foxp3 + cells (and therefore T FR cells) located within the GC borders in Pdcd1 −/− mice than in wild-type mice (Fig. 3g) . However, as this was proportional to the greater number of T FR cells in PD-1-deficient mice determined by flow cytometry, these data demonstrated that PD-1-deficient T FR cells were not defective in homing to GCs and were able to enter the GC like wild-type T FR cells.
The location of Foxp3 + T FR cells in the GC did not differ significantly for wild-type and Pdcd1 −/− mice (Fig. 3h) . In both wild-type and Pdcd1 −/− mice, the Foxp3 + cells tended to reside near the GC border, with more than half of the nuclei of Foxp3 + cells being positioned within 10 µm of the border. Furthermore, when we quantified CXCR5 fluorescence by flow cytometry, we found similar CXCR5 expression on wild-type and Pdcd1 −/− T FR cells (Fig. 3i) , which indicated a similar potential for these cells to respond to chemokine cues to migrate to GCs. Together these data indicated that the lymph nodes of immunized Pdcd1 −/− mice had more T FR cells and that these Pdcd1 −/− T FR cells were able to migrate into GCs to regulate B cell responses.
PD-1-deficient T FR cells more potently inhibit antibody
We next assessed the function of T FR cells from wild-type and Pdcd1 −/− mice. T FR cells have higher expression of the T reg cellassociated receptor GITR on the surface than do T FH cells, which allowed us to separate T FH cells and T FR cells in a similar manner to that of intracellular staining for Foxp3 (Fig. 4a) . For functional studies, we sorted T FR cells from immunized mice by defining the lymph node CD4 + ICOS + CXCR5 + CD19 -GITR + population as T FR cells and the CD4 + ICOS + CXCR5 + CD19 -GITR -population as T FH cells (Fig. 4b) . Sorting in this way resulted in a considerable abundance of Foxp3 mRNA in the GITR + (T FR ) population but essentially no Foxp3 mRNA in the GITR -(T FH ) population (Fig. 4b) , which confirmed the utility of this gating strategy for the isolation of T FR cells and T FH cells for functional assays. Furthermore, we were able to use this sorting strategy to compare wild-type and PD-1-deficient T FR cells, as GITR expression was identical on wild-type and PD-1-deficient T FR cells (Supplementary Fig. 3) .
T FR cells have high expression of Blimp-1 and moderate expression of Bcl-6 (ref. 21 ). Bcl-6 and Blimp-1 reciprocally modulate each other 2 ; inhibition of Blimp-1 by Bcl-6 is essential for maintenance of (Fig. 4e) . In addition, we compared expression of the transcription factor IRF4 in wild-type T FR cells with that in Pdcd1 −/− T FR cells, as Blimp-1 and IRF4 synergistically control the differentiation and effector functions of T reg cells 26 . We found higher expression of Irf4 mRNA in Pdcd1 −/− T FR cells than in wild-type T FR cells (Fig. 4f) . IRF4 is essential for the suppressive ability of T reg cells 26 . To determine if higher expression of Irf4 mRNA in Pdcd1 −/− T FR cells resulted in more suppression of the proliferation of T cells, we set up an in vitro suppression assay in which we cultured sorted wild-type CD4 + CD62L + Foxp3 -responder T cells (from unimmunized mice) labeled with the cytosolic dye CFSE, wild-type GL7 -B cells from MOG-immunized wild-type mice and T FR cells sorted from MOGimmunized wild-type or Pdcd1 −/− mice, together with antibody to CD3 (anti-CD3) and anti-IgM. The responder T cells had substantial upregulation of the expression of CD69 after 3 d of culture with wildtype B cells. However, when we added wild-type T FR cells (at a ratio of 1:1:1 with responder T cells and B cells as described above), the CD69 expression on the responder T cells was much lower (Fig. 4g) , consistent with the function of T FR cells in suppressing T cell activation. CD69 upregulation was inhibited to an even greater extent in responder T cells cultured with Pdcd1 −/− T FR cells. Moreover, Pdcd1 −/− T FR cells attenuated the proliferation of responder T cells, in contrast to wild-type T FR cells, which did not inhibit the proliferation of responder T cells during the 3-day culture period (Fig. 4h) .
Although T FR cells are thought to inhibit the GC response in vivo, it is unclear whether T FR cells directly inhibit the differentiation of T cells, the function of T FH cells, the activation of B cells or all three. To assess the ability of T FR cells to suppress antibody production by B cells in vitro, we cultured wild-type GL7 -B cells with wild-type T FH cells for 6 d in the presence or absence of T FR cells (all from MOG-immunized mice), anti-IgM and anti-CD3. Wild-type B cells produced large amounts of IgG when cultured with wild-type T FH cells plus anti-IgM and anti-CD3 (Fig. 4i) . No significant IgG was produced when we used naive CD4 + T cells in these experiments (Fig. 4j) . When we added T FR cells to the wells along with T FH cells, almost no IgG was produced. The T FR cell-mediated suppression was not due to the sequestering of anti-CD3 because there was equally good suppression at the two doses of anti-CD3 tested (Fig. 4i) and anti-CD3 was still present on the surface of the T FH cells at the end of the suppression assay ( Supplementary Fig. 4) . Pdcd1 −/− T FR cells suppressed IgG production more than wild-type T FR cells did at ratios Fig. 4k) , with PD-1-deficient T FR cells resulting in 50% lower IgG production than that of wild-type T FR cells. Together these data demonstrated not only that Pdcd1 −/− mice had more T FR cells but also that those Pdcd1 −/− T FR cells had greater suppressive capacity.
PD-1 controls T FR cells in the blood
One possible explanation for the greater abundance of T FR cells in lymph nodes of immunized PD-1-deficient mice might be that Pdcd1 −/− T FR cells were unable to exit the lymph node. Functional T FH cells can be found in the blood of humans as well as mice 6, 7, 9 , but whether T FR cells circulate in the blood of humans or mice is not yet known. We found a distinct population of T FH cells, as well as a smaller population of T FR cells, in the blood of wild-type mice immunized with MOG (Fig. 5a,b) . When we assessed the kinetics of the population expansion of T FH cells and T FR cells in the lymph node and blood of mice after MOG immunization, we found that the frequency of T FR and T FH cells increased in the draining lymph nodes of immunized wild-type mice over a 10-day period, and that T FH cells, but not T FR cells, increased substantially (by percentage) in the blood over this time (Fig. 5b) . Thus, without antigenic stimulus, the ratio of T FR cells to T FH cells in the blood was fairly high (sometimes >1:1), but after the addition of a stimulus, the population expansion of T FH cells in the blood was greater than that of T FR cells in the blood, so that the ratio of T FR cells to T FH cells was about 1:5. To investigate whether wild-type T FH cells and T FR cells in the blood were quiescent or actively in the cell cycle, we assessed Ki67 expression in T FH cells and T FR cells from the draining lymph nodes and blood at 7 d after immunization. T FH cells from the draining lymph nodes had higher Ki67 expression than did those in the blood (Fig. 5c) . T FH cells and T FR cells in the blood and T FR cells from the draining lymph nodes had similar expression of Ki67.
Next we investigated whether T FR cells in the blood were inhibited to the same degree by PD-1 signaling as were T FR cells from the lymph nodes. We immunized wild-type and Pdcd1 −/− mice with MOG and 7 d later analyzed T FH cells and T FR cells from the blood. In wild-type mice, ~2-3% of CD4 + Foxp3 -CD19 -cells in the blood were T FH cells, but in the Pdcd1 −/− mice, ~4-5% were T FH cells (Fig. 5d) . This greater frequency of Pdcd1 −/− T FH cells in blood was in contrast to results obtained for the lymph nodes, where Pdcd1 −/− mice had a frequency of T FH cells similar to, if not less than, that of wild-type mice (Fig. 1e) . Notably, T FR cells constituted ~3% of all Foxp3 + cells in the blood of wild-type mice but >7% of Foxp3 + cells in the blood of Pdcd1 −/− mice (Fig. 5d,e) . The greater frequency of Foxp3 + cells seemed to be specific to the subset of T FR cells in the blood, as the frequency of Foxp3 + cells in the ICOS + CXCR5 -(ICOS + ) and ICOS -CXCR5 -naive cell gates was not greater in Pdcd1 −/− mice (Fig. 5f ). Together these data indicated that both T FR cells and T FH cells were present in the blood of mice and that both subsets were repressed by PD-1 signaling.
To investigate whether T FH and T FR cells in the blood had a central memory phenotype, we analyzed surface expression of CD62L and CD44. About 60% of wild-type and Pdcd1 −/− T FR cells in the blood had high expression of CD62L (Supplementary Fig. 5 ). This was in contrast to the finding that >90% of ICOS -CXCR5 -naive cells had high expression of CD62L. Pdcd1 −/− T FH cells had lower expression of CD62L than did wild-type T FH cells. All wild-type and Pdcd1 −/− T FR cells in the blood had high expression of CD44, but Pdcd1 −/− T FR cells in the blood had slightly lower surface expression than did their wild-type counterparts (Supplementary Fig. 5 ). Furthermore, T FR cells in the blood had lower expression of PD-1 than did T FR cells from the lymph nodes (Supplementary Fig. 5 ). Together these data indicated that T FR cells in the blood were able to have a central memory homing phenotype. The greater frequency of T FR cells in Pdcd1 −/− mice led us to investigate which PD-1 ligand was critical for controlling the generation of T FR cells in the lymph nodes and blood. We first assessed the expression of PD-L1 and PD-L2 on B cells and DCs present in draining lymph nodes of immunized wild-type mice, because both B cells and DCs contribute to the proper differentiation and maintenance of T FH cells in the lymph nodes 1 . It is not yet clear whether B cells or DCs or both are needed for the differentiation and/or maintenance of T FR cells. To study GC B cells, we immunized mice with NP-OVA subcutaneously and, 12 d later, assessed the expression of PD-L1 and PD-L2 on Fas + GL7 + CD19 + GC B cells, as well as on CD138 + plasma cells from the draining lymph nodes. We found that all B cell subsets had high expression of PD-L1, but only GC B cells had high expression of PD-L2 (Fig. 6a) . To quantify the expression of PD-L1 and PD-L2 on DCs, we immunized mice with NP-OVA and analyzed DC populations from the draining lymph node 3 d later. Both CD8α + and CD8α -DC populations had high expression of PD-L1 and moderate expression of PD-L2 (Fig. 6b) . A subpopulation of CD8α -DCs had high expression of PD-L2.
To determine which ligand was important for the generation of T FH cells and T FR cells, we immunized wild-type mice, PD-L1-deficient (Cd274 −/− ) mice and PD-L2-deficient (Pdcd1lg2 −/− ) mice with MOG and analyzed T FH cells and T FR cells in the draining lymph nodes and blood 7 d later. The frequency of T FH cells in the lymph nodes of Cd274 −/− and Pdcd1lg2 −/− mice was similar to that of wild-type mice (Fig. 6c) and Pdcd1 −/− mice (Fig. 1e) . Cd274 −/− mice, but not Pdcd1lg2 −/− mice, had more T FH cells in the blood, similar to that of Pdcd1 −/− mice (Fig. 5e) . Cd274 −/− mice, but not Pdcd1lg2 −/− mice, had more T FR cells in the lymph nodes as well as the blood (Fig. 6d) . Like Pdcd1 −/− mice, Cd274 −/− mice did not 
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have a greater frequency of any non-T FR Foxp3 + effector cell in the blood (Fig. 6e) . These studies demonstrated that PD-L1, but not PD-L2, was responsible for controlling T FR cells in the lymph nodes and blood.
Blood T FH and T FR cells require CD28 and ICOS signals
We further investigated the costimulatory requirements for T FR cells in the blood, focusing on the effects of costimulation by CD28 and ICOS on T FR populations in the blood because of the important roles of these costimulatory receptors in controlling T FH cells and T FR cells from the lymph nodes. Cd28 −/− mice are deficient in T FH cells and T FR cells in the lymph nodes 21 , and Icos −/− mice are deficient in T FH cells in the lymph nodes 24 . We analyzed Cd28 −/− mice and Icos −/− mice for the presence of T FR cells in the lymph nodes and blood 7 d after immunization with MOG. In wild-type mice, there were fewer T FH cells and T FR cells in the blood than in the draining lymph nodes (Fig. 7a,b) . Icos −/− mice had considerably fewer T FR cells (and T FH cells) in the blood, as well as the lymph nodes (Fig. 7a-c) . Cd28 −/− mice had similar considerable deficiencies in the frequency of T FR cells and T FH cells in both lymph nodes and blood (Fig. 7d-f) . Thus, ICOS and CD28 supplied essential costimulatory signals for T FR cells and T FH cells in the blood as well as the lymph nodes.
Enhanced suppression by Pdcd1 −/− T FR cells in the blood in vivo
We next investigated the function of T FR cells in the blood in humoral immune responses. Because T FH cells in human blood can function in the activation and antibody production of B cells in vitro 6, 7 , we investigated whether T FR cells in the circulating blood contributed to the suppression of antibody production in vivo. To assess this, we designed transfer experiments in which we immunized wild-type donor mice with NP-OVA subcutaneously and 8 d later sorted T FR (CD4 + ICOS + CXCR5 + GITR + CD19 -) cells and T FH (CD4 + ICOS + CXCR5 + GITR -CD19 -) cells from the blood (Fig. 8a) . We transferred those cells into (Fig. 8a) . Without transfer of T FH cells or T FR cells from the blood, Cd28 −/− mice were unable to produce large amounts of NP-specific IgG (Fig. 8b) . The transfer of T FH cells from the blood alone resulted in much higher titers of NP-specific IgG. Transfer of T FH cells from the blood led to substantial production of IgG1, but also smaller increases in the production of immunoglobulins of other isotypes (data not shown). Transfer of T FR cells from the blood along with T FH cells from the blood resulted in robust inhibition of the production of NP-specific antibody (Fig. 8b) , which demonstrated the potent regulatory ability of T FR cells from the blood in suppressing antibody production. To evaluate the effect of T FR cells on the generation of plasma cells, we collected draining lymph nodes, spleens and bone marrow from recipient mice 24 d after immunization and quantified plasma cells. CD138 + plasma cells were absent from the lymph nodes of immunized Cd28 −/− mice (Fig. 8c,d ). The transfer of T FH cells from the blood resulted in sizable populations of plasma cells in the draining lymph nodes, spleen and bone marrow (Fig. 8c,d) . T FR cells from the blood almost completely prevented formation and/or survival of plasma cells in all organs tested.
Next we transferred T FH cells and/or T FR cells from the blood into Tcra −/− recipients. The transfer of 4 × 10 4 T FH cells resulted in a higher titer of NP-specific IgG than that of an NP-OVAimmunized wild-type mouse in most experiments (Fig. 8e) . The robust antibody production elicited by T FH cells from the blood depended on the 'follicular program' because transfer of total CD4 + T cells from Cxcr5 −/− mice or CD4 + CD62L + CXCR5 -Foxp3 -naive cells from wild-type mice resulted in background concentrations of antibody in these experiments (Fig. 8e) . When we transferred T FR cells from the blood together with T FH cells from the blood, the titers of NP-specific antibody were much lower (Fig. 8e) , which demonstrated the suppressive ability of the T FR cells. The T FR cells from the blood resulted in lower frequencies of both plasma cells in the spleen (Fig. 8f) and T FH cells in the lymph nodes (Fig. 8g) . When we compared the function of T FH cells from the blood and T FH cells from the draining lymph nodes after transfer into Tcra −/− recipients, we found that T FH cells from the blood had a greater ability to promote the 
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A r t i c l e s production of NP-specific IgG (Fig. 8h) . The suppression of T FH cells by T FR cells also depended on the 'follicular program' in these cells because neither CD25 + CD62L + T reg cells from the blood of Cxcr5 −/− mice (data not shown) nor CXCR5 -Foxp3 + T reg cells from the blood of Foxp3-GFP reporter mice had the same suppressive ability as that of T FR cells from the blood of wild-type mice (Fig. 8i) . Finally, we investigated the suppressive ability of PD-1-deficient blood T FR cells in vivo, as PD-1-deficient T FR cells from the lymph node suppressed antibody production more potently than did wild-type T FR cells from the lymph node in vitro. We adoptively transferred 4 × 10 4 wild-type T FH cells from the blood alone or together with 1.5 × 10 4 T FR cells from the blood of wild-type or Pdcd1 −/− mice into Cd28 −/− or Tcra −/− recipients and immunized the recipients as described above (Fig. 8a) . PD-1-deficient T FR cells inhibited antibody production to a greater extent than did wild-type T FR cells in Cd28 −/− recipients (Fig. 8j) and Tcra −/− recipients (Fig. 8k) , which demonstrated their greater suppressive ability. Together these data showed that T FR cells from the blood potently inhibited antibody production in vivo and that PD-1 deficiency resulted in enhanced suppressive ability of T FR cells. 16, 18, 19 . It is likely that a greater abundance of T FR cells in PD-1-deficient mice may have contributed to the greater abundance of T FH cells and may explain conflicting data. For example, published studies have described a greater abundance of CD4 + CXCR5 + cells in Peyer's patches of PD-1-deficient mice 18 . However, after transfer, those cells were nonfunctional in supporting IgA production. A greater abundance of T FR cells in the T FH gate in PD-1-deficient Peyer's patches may explain those data.
T FR cells depend on the adaptor SAP, CD28 and Bcl-6 for differentiation 21, 22 . However, the pathways that limit the differentiation of T FR cells are less clear. Only the transcription factor Blimp-1 has been shown to inhibit the differentiation of T FR cells 21 . Here we have identified PD-1 as a surface receptor that inhibited the development of T FR cells. Our adoptive-transfer studies demonstrated a cell-intrinsic role for PD-1 in the differentiation of T FR cells from Foxp3 + T reg cells. We hypothesize that rather than simply inhibiting responses, the PD-1 pathway may act as a molecular switch that controls cell-fate 'decisions' . The integration of signals through PD-1, TCRs and cytokine receptors may direct differentiation into various T cell subsets. For example, PD-L1 can promote the differentiation of induced T reg cells from naive T cells [10] [11] [12] [13] [14] 29 . However, we found that PD-1 inhibited the differentiation of T FR cells. T FR cells arise from natural T reg cells 21 . Therefore, our studies suggest that PD-1 may have distinct roles in the differentiation of induced and natural T reg cells.
Because of the recent discovery of T FR cells, there is a lack of knowledge about T FR cell biology, so we developed assays to analyze the function of T FR cells. T FR cells have the potential to inhibit the activation of naive T cells, T FH cell function and/or the activation of B cells. Here we used specific assays for T FR cell function in vitro and found that T FR cells from the lymph nodes were potent at inhibiting antibody production but not effective at suppressing T cell activation. PD-1-deficient T FR cells inhibited the activation of naive T cells and attenuated antibody production in vitro to a greater extent than did wild-type T FR cells. Furthermore, our studies demonstrated the dynamic control of antibody production by T FH cells and T FR cells. Initially, our attempts to activate B cells in vitro with total CD4 + CXCR5 + cells resulted in little IgG. However, when we separated T FH cells from T FR cells, we detected abundant IgG. Moreover, we found that in vitro and in vivo, the ratio of T FR cells to T FH cells, not the individual numbers of each, seemed to be critical in determining the extent of humoral immunity. Therefore, analyzing this ratio may be useful in predicting the extent of a humoral immune response.
We found substantial populations of T FR cells in the blood of mice. Many reports have described T FH cells in the circulation of humans 6, 7 , and one has described them in the blood of mice 9 . To our knowledge, our work is the first description of functional T FR cells in the blood of any organism. T FH cells in human blood have been shown to stimulate antibodies in vitro. Some studies have shown more efficient B cell antibody production by T FH cells in the blood than by CXCR5 -cells 6, 7 , whereas others have found no difference between T FH cells from the blood and CXCR5 -cells 30 . Such differences may relate to the ratio of T FH cells to T FR cells in those experiments. Here we found that the generation of T FH cells and T FR cells in the blood required signaling through ICOS and CD28, two costimulatory receptors essential for controlling T FH cells in the lymph nodes.
Our transfer studies showed that T FR cells from the blood were functional and were able to regulate antibody production in vivo.
To study the function of T FR cells, we transferred T FH cells from the blood alone or with T FR cells into Cd28 −/− or Tcra −/− mice, which lack T FH cells and T FR cells in both blood and lymph nodes. Although it was technically challenging, this approach allowed us to analyze the function of T FH cells and T FR cells separately from differentiation. T FR cells from the blood were extremely potent at inhibiting T FH cell-mediated production of antibody, even when relatively few cells were transferred. We hypothesize that T FR cells from the blood are a central memory pool that can be used to modulate humoral immunity, analogous to Foxp3 + cells with regulatory memory 31 . The high expression of CD62L and CD44 on T FR cells from the blood, along with their ability to home to lymph nodes, supports this idea. T FR cells from the blood would be able to home to lymph nodes and suppress early B cell responses before natural T reg cells differentiated into T FR cells.
Beyond their ability to directly suppress antibody responses, T FR cells may be instrumental in determining B cell fate. For example, T FR cells may direct the differentiation of GC B cells away from plasma cells into memory B cells. If T FR cells direct B cell fate, this would have implications for vaccines. Additionally, analyzing the ratio of T FR cells to T FH cells may be used to predict the quality and quantity of humoral immune responses in vivo. Furthermore, therapy with T FR cells has potential for patients suffering from autoimmunity. By transferring T FR cells, it may be possible to suppress autoantibody production while leaving other arms of the immune system intact. In summary, T FR cells are potent suppressors of humoral immunity and are controlled by PD-1. Further work is needed to determine how modulation of these cells may be used therapeutically to enhance protective immunity and long-term memory or to inhibit autoimmune diseases.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Mice. Mice 6-10 weeks of age were used for all experiments. Wild-type C57BL/6 mice and Tcra −/− mice were from The Jackson Laboratory. Pdcd1 −/− , Cd274 −/− and Pdcd1lg2 −/− mice on the C57BL/6 background were generated in the Sharpe laboratory [32] [33] [34] . Icos −/− mice 35 and Cd28 −/− mice 36 were generated as described. The 2D2-Foxp3-GFP mice were generated in the Sharpe laboratory by the crossing of Foxp3-GFP reporter mice 37 with 2D2 mice 38 . All mice were used according to the Harvard Medical School Standing Committee on Animals and National Institutes of Animal Healthcare Guidelines. Animal protocols were approved by the Harvard Medical School Standing Committee on Animals.
Immunization. For immunization with MOG, mice were given subcutaneous injection of 100 µg MOG (amino acids 35-55; University of California Los Angeles Biopolymers Facility) emulsified (at a ratio of 1:1) in an emulsion of Mycobacterium tuberculosis strain H37RA complete Freund's adjuvant (Difco) in their flanks. Then, 7 d later, mice were killed and inguinal lymph nodes (draining lymph nodes) and/or spleens were collected for flow cytometry. Blood was collected by cardiac puncture with a 1-cc syringe, and cells of the immune system were isolated by sucrose density centrifugation with Lymphocyte Separation Media (MP Biomedicals). For NP-OVA immunizations, 100 µg NP 18 -OVA (Biosearch Technologies) was used in an emulsion (at a ratio of 1:1) in M. tuberculosis H37RA complete Freund's adjuvant and was injected as described for MOG.
Enzyme-linked immunosorbent assay. For quantification of antibody production in vitro, total IgG was quantified in culture supernatants with a total IgG capture antibody (1010-01; Southern Biotech) and alkaline phosphataseconjugated total IgG detection antibody (1030-04; Southern Biotech). For analysis of antibody production in vivo, serum was collected from mice at various time points. NP-specific antibody titers were measured by incubation of serum for 1 h in enzyme-linked immunosorbent assay plates coated with NP 16 -BSA (Biosearch Technologies), followed by incubation with alkaline phosphataseconjugated IgG-detection antibodies (1030-04; Southern Biotech). A standard curve was generated with antibody from an NP-specific IgG1 hybridoma (a gift from M. Carroll). That standard curve was used for the approximation of all IgG-subtype antibodies in the linear range of detection with a Spectramax Elisa plate reader (Molecular Devices).
Flow cytometry. Cells from lymphoid organs were isolated and resuspended in staining buffer (PBS containing 1% FCS and 2 mM EDTA) and were stained with the following directly labeled antibodies: anti-CD4 (RM4-5), anti-ICOS (15F9), anti-CD19 (6D5), anti-PD-1 (RMP1-30), anti-PD-L1 (10F.9G2), CD69 (H1.2F3; all from Biolegend); anti-Foxp3 (FJK-16S) and anti-Bcl-6 (mGI191E; both from eBioscience); and anti-Fas (Jo2), anti-GL7 (GL7) and anti-Ki67 (B56; all from BD Biosciences). For staining of CXCR5, biotinylated anti-CXCR5 (2G8; BD Biosciences) was used, followed by streptavidin-Brilliant Violet 421 (Biolegend). For intracellular staining, a Foxp3 Fix/Perm kit was used (eBioscience) after surface staining. All flow cytometry data were analyzed with an LSR II (BD Biosciences) with standard filter sets and were further analyzed with FlowJo software (TreeStar).
Confocal microscopy. Draining lymph nodes were embedded in optimum cutting temperature compound, and sections 8 µm in thickness were cut, fixed with 4% paraformaldehyde and stained, followed by imaging on a Zeiss LSM 510 confocal microscope by acquisition of z-stacks 0.5 µm in thickness with a 40× oil objective. GCs were quantified by drawing of outlines around GL7 + IgD − areas in the B cell zone. For quantification of Foxp3, GC zones were determined and z-stack images were scrolled through for identification of large Foxp3 + spots. Axiovision (Zeiss) software was used for measurement of the distance from GC borders. For micrographs, single z slices were contrasted in a linear way and merged images were made in Adobe photoshop. Enlargements indicate digital enlargements made with Adobe photoshop.
Quantitative PCR. Standard TaqMAN probes (Applied Biosystems) and an ABI FasT9500 QPCR system were used according to the manufacturers' instructions for quantitative PCR. The abundance of mRNA was normalized to that of HPRT (hypoxanthine guanine phosphoribosyl transferase) or β 2 -microglobulin, and the change-in-threshold (∆C T ) method was used for quantification of mRNA (2 -∆∆CT ). The abundance of RNA was normalized to that in naive T cells.
In vitro suppression assay. Cell populations were sorted to a purity of 99% on a FACSAria II (BD Biosciences). For assays of suppression by T FR cells, sorted cells were counted on an Accuri cytometer (BD Biosciences) by gating of live cells only, and 1 × 10 5 GL7 -B cells from draining lymph nodes of wild-type mice immunized with MOG 7 d before, 1 × 10 5 CD4 + CD62L + Foxp3 -T responder cells from unimmunized wild-type Foxp3-GFP reporter mice (labeled with CFSE (carboxyfluorescein diacetate succinimidyl ester; Invitrogen)), and 1 × 10 5 T FR cells from the draining lymph nodes of mice immunized with MOG 7 d before were plated with 2 µg/ml soluble anti-CD3 (2C11; BioXcell) and 5 µg/ml anti-IgM (115-006-020; Jackson Immunoresearch). After 3 d, cells were collected and stained with anti-CD4 (RM4-5; Biolegend) and anti-CD19 (6D5; Biolegend). The responder T cells were identified as CFSE + cells, and the percent divided cells was determined by flow cytometry by drawing of a gate outside a reference CFSE peak from unstimulated CFSE + cells. For in vitro antibody suppression, GL7 -B cells from wild-type MOG-immunized mice were plated with T FH cells and/or T FR cells pooled from MOG-immunized wild-type or Pdcd1 −/− mice and 2 µg/ml soluble anti-CD3 and anti-IgM (as described above). After 6 d, supernatants were collected for antibody analysis by enzyme-linked immunosorbent assay.
Adoptive transfer. For the transfer of 2D2 T reg cells, 2 × 10 5 CD4 + CXCR5 -Foxp3 + cells were sorted from the spleens of unimmunized wild-type or Pdcd1 −/− 2D2 Foxp3-GFP reporter mice and adoptively transferred intravenously into wild-type recipients, which were then immunized with MOG. For adoptive transfer of T FH cells and T FR cells from the blood, wild-type mice were immunized subcutaneously with NP-OVA as described above, and 8 d later blood was collected by cardiac puncture. T FH cells and T FR cells were sorted as described above. T FH cells (4 × 10 4 ) from the blood, alone or together with T FR cells (2 × 10 4 ) from the blood, were transferred into Cd28 −/− or Tcra −/− mice, unless specified otherwise. The recipient mice were immunized with NP-OVA as described above. Serum and organs were collected and analyzed by enzyme-linked immunosorbent assay or flow cytometry. Statistical analysis. Unpaired Student's t-test was used for all comparisons. P values of less than 0.05 were considered statistically significant.
